These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20697803)

  • 1. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
    Martin LA; Davies GL; Weigel MT; Betambeau N; Hills MJ; Salter J; Walsh G; A'Hern R; Dowsett M
    Breast Cancer Res Treat; 2010 Oct; 123(3):829-36. PubMed ID: 20697803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
    Lustberg MB; Povoski SP; Zhao W; Ziegler RM; Sugimoto Y; Ruppert AS; Lehman AM; Shiels DR; Mrozek E; Ramaswamy B; Layman RM; Brueggemeier RW; Shapiro CL
    Clin Breast Cancer; 2011 Aug; 11(4):221-7. PubMed ID: 21729671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
    Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
    Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
    Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
    Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
    Generali D; Buffa FM; Deb S; Cummings M; Reid LE; Taylor M; Andreis D; Allevi G; Ferrero G; Byrne D; Martinotti M; Bottini A; Harris AL; Lakhani SR; Fox SB
    Br J Cancer; 2014 Jul; 111(1):46-54. PubMed ID: 24874483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
    Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
    Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
    Chow LW; Loo WT; Wai CC; Lui EL; Zhu L; Toi M
    Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S298-301. PubMed ID: 16507397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
    Brandão RD; Veeck J; Van de Vijver KK; Lindsey P; de Vries B; van Elssen CH; Blok MJ; Keymeulen K; Ayoubi T; Smeets HJ; Tjan-Heijnen VC; Hupperets PS
    Breast Cancer Res; 2013 Apr; 15(2):R29. PubMed ID: 23566419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    Hamy AS; Tury S; Wang X; Gao J; Pierga JY; Giacchetti S; Brain E; Pistilli B; Marty M; Espié M; Benchimol G; Laas E; Laé M; Asselain B; Aouchiche B; Edelman M; Reyal F
    J Clin Oncol; 2019 Mar; 37(8):624-635. PubMed ID: 30702971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.
    Dowsett M; Bundred NJ; Decensi A; Sainsbury RC; Lu Y; Hills MJ; Cohen FJ; Veronesi P; O'Brien ME; Scott T; Muchmore DB
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):961-6. PubMed ID: 11535548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
    Anderson H; Hills M; Zabaglo L; A'hern R; Leary AF; Haynes BP; Smith IE; Dowsett M
    Ann Oncol; 2011 Aug; 22(8):1770-6. PubMed ID: 21285137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.
    Chow LW; Yip AY; Chu WP; Loo WT; Toi M
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):112-9. PubMed ID: 21236344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant therapy with celecoxib to women with early stage breast cancer.
    Tfayli A; Yang J; Kojouri K; Kesserwan C; Jafari M; Ozer H
    Neoplasma; 2008; 55(2):122-6. PubMed ID: 18237249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
    Allevi G; Strina C; Andreis D; Zanoni V; Bazzola L; Bonardi S; Foroni C; Milani M; Cappelletti MR; Gussago F; Aguggini S; Giardini R; Martinotti M; Fox SB; Harris AL; Bottini A; Berruti A; Generali D
    Br J Cancer; 2013 Apr; 108(8):1587-92. PubMed ID: 23579222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
    Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
    Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of COX-2 inhibition in breast cancer treatment and prevention.
    Arun B; Goss P
    Semin Oncol; 2004 Apr; 31(2 Suppl 7):22-9. PubMed ID: 15179621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.